glp-1 news september 30 2025 GLP-1 Drugs: 2025 Pulse Survey (U.S.) Lilly hikes revenue forecasts on

Furthermore, by intermediating the contact between the consumer and compounding pharmacies, they act directly in the dispensing of medicines as if they themselves were compounding pharmacies or acted on their behalf

Recent survey data reveal that a substantial proportion of the public continues to attribute excess weight to personal responsibility, while a growing segment supports disease classification for obesity

November 2025 The White Houses newly announced agreements with Novo Nordisk and Eli Lilly promise to lower the prices of popular GLP-1 medications such as Wegovy (semaglutide) and Zepbound (tirzepatide)

Prior authorization: Your providers office handles this submission on your behalf, but incomplete documentation is a common cause of delays

To enhance the safety of GLP-1-RAs in clinical practice, it is critical to carefully select patients and adequately manage gastrointestinal side effects, despite the medications' typically excellent tolerance [80]

Because almost everyone waited the full 50 minutes